What OTR Therapeutics does

OTR Therapeutics is a clinical-stage biotechnology company headquartered in Shanghai, China, that operates a dual-track business model combining internal drug discovery with strategic acquisition of external preclinical assets. Founded in March 2025 by Dr. Zhui Chen (ex-Abbisko Therapeutics), Dr. Shannon Chuai (ex-Burning Rock Biotech, NASDAQ: BNR), and Dr. Yuan Shi (11 years at Eli Lilly), the company is developing differentiated oral small-molecule therapeutics across oncology, immunology & inflammation, cardiometabolic diseases, and neurological diseases. Its core scientific capability is a proprietary oral small-molecule discovery platform augmented by computer-aided drug design (SBDD, ligand-based modeling, molecular dynamics, cheminformatics), RAG-based biomedical knowledge systems, and intelligent agents for literature mining and experimental design.

The company's lead asset, OTR-8100, is an oral anti-tumor small-molecule inhibitor that received IND clearance from China's NMPA in May 2026, triggering a Phase Ib/II trial in advanced malignant tumors. The pipeline is built through both internal discovery and external asset curation, including a December 2025 acquisition of a preclinical neurology program described as best-in-class potential.

OTR is pre-revenue and monetizes through partnership economics: upfront payments, preclinical/development/regulatory/commercial milestones, and tiered royalties on worldwide net sales of commercialized products. The flagship deal is a December 2025 multi-program strategic collaboration with Zealand Pharma for metabolic disease therapeutics, worth $20-30M upfront and up to $2.5B in potential milestones plus single-digit royalties, with Zealand Pharma responsible for global clinical development and commercialization while OTR retains discovery and preclinical ownership. The company is venture-backed by True Light Capital (Temasek subsidiary), LAV (Lilly Asia Ventures), Pfizer Ventures, and Sirona Capital following a $100M Series A in June 2025, and operates from a centralized R&D hub in Shanghai's Zhangjiang Hi-Tech Park with stated collaboration reach across the US, Europe, and Asia.

Name

OTR Therapeutics

Legal name

OTR Therapeutics (Shanghai) Co., Ltd.

Website

https://otr-tx.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

11–50 employees

Short description

OTR Therapeutics is a Shanghai-based, clinical-stage biotech founded in 2025 that develops oral small-molecule therapeutics across oncology, immunology, cardiometabolic, and neurological diseases, monetizing through pharma partnerships and royalties rather than direct commercialization.

Ownership category

akta.pro rank

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Partnership milestone payments: OTR receives upfront payments and is eligible for preclinical, development, regulatory, and commercial milestone payments from partners. The Zealand Pharma partnership includes $20-30M upfront and potential milestones up to $2.5B, with majority representing commercial milestones.
2. Royalty revenue from product sales: OTR is eligible to receive tiered single-digit royalties on worldwide net sales of any commercialized products resulting from collaborations, such as the Zealand Pharma metabolic disease partnership.
3. Future product commercialization: Pre-revenue company with potential for direct commercialization of differentiated therapies developed internally or acquired through external partnerships, targeting oncology, immunology & inflammation, and cardiometabolic diseases.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

OTR Therapeutics discovers and acquires distinctive preclinical small-molecule assets and advances them through its proprietary oral drug discovery platform, then partners with global pharmaceutical companies for clinical development, regulatory submissions, and commercialization. Its lead asset OTR-8100, an oral anti-tumor small-molecule inhibitor, received IND clearance from China's NMPA in May 2026; pipeline programs target oncology, immunology & inflammation, cardiometabolic, and neurological diseases.

Product overview

OTR Therapeutics is a clinical-stage biotechnology company operating a dual-track model combining internal R&D with strategic acquisition of external innovations. The company focuses on developing differentiated therapies across three therapeutic areas: oncology, immunology & inflammation, and cardiometabolic diseases. The core product OTR-8100 is an oral anti-tumor small-molecule candidate that recently entered clinical development. The pipeline includes multiple innovative assets acquired through external partnerships, with programs spanning preclinical to early clinical stages. The company leverages its proprietary discovery platform and R&D hub in Shanghai's Zhangjiang Hi-Tech Park to accelerate development of high-impact therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• OTR-8100 A novel oral anti-tumor small-molecule inhibitor targeting multiple solid tumors; demonstrated superior in vitro and in vivo efficacy and compelling combination therapy potential in preclinical studies. Advanced into a Phase Ib/II clinical study in China in patients with advanced malignant tumors following NMPA IND clearance. Acquired by OTR through external partnership and is the company's lead clinical asset.

Quantifiable outcome

• OTR-8100 demonstrated superior in vitro and in vivo efficacy and compelling combination therapy potential in preclinical studies
• +2 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature1 record

Partnerships

One partnership is on record.

• Zealand PharmacoreStrategic or Co-development Partner · 11 December 2025Multi-program strategic collaboration and license agreement to discover and develop novel therapeutics for metabolic diseases. OTR Therapeutics leverages its proprietary discovery platform to lead research and preclinical development while Zealand Pharma assumes responsibility for clinical development, regulatory submissions, and commercialization worldwide. OTR receives $20M upfront (potentially $30M), with potential total consideration up to $2.5 billion including preclinical, development, regulatory, and commercial milestones, plus tiered single-digit royalties on worldwide net sales.

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Hutchmed (HUTCHMED): Hong Kong- and Shanghai-listed biopharma developing oncology and immunology small molecules with global BD-led commercialization. Comparable China-anchored clinical-stage model with major pharma partnerships (e.g., AstraZeneca, Lilly).
• BridgeBio Pharma: Clinical-stage biotech advancing small molecules for genetic and metabolic diseases with a partnership and licensing-driven model. Comparable on stage, modality, and emphasis on capital-efficient development across multiple programs.
• Terns Pharmaceuticals: Shanghai- and San Mateo-based clinical-stage biotech developing small-molecule therapies in oncology and metabolic disease. Directly comparable in geography, modality (oral small molecules), and therapeutic focus including cardiometabolic.
• Roivant Sciences: Platform biotech that in-licenses and develops therapeutic programs across multiple indications via subsidiary 'Vants'. Highly comparable to OTR's build-and-buy, capital-efficient, partnership-led operating model.
• Abbisko Therapeutics: Shanghai-based clinical-stage biotech co-founded by OTR's CEO Dr. Zhui Chen; focused on precision oncology small molecules. Closely comparable in geography, therapeutic focus, and operating philosophy (capital-efficient R&D, BD-led model).
• Insilico Medicine: AI-driven drug discovery company also headquartered in Shanghai with a clinical-stage pipeline of small molecules. Comparable on the AI-augmented discovery platform positioning and on regional base and therapeutic breadth.

Broad incumbents

• BeiGene: Large China-US oncology biotech with approved products (Brukinsa) and a global clinical/commercial footprint. Comparable in therapeutic focus (oncology) and Shanghai/Beijing roots, though at substantially larger scale and with direct commercialization.
• Eli Lilly: Global incumbent with deep cardiometabolic and oncology franchises (Mounjaro/Zepbound, Verzenio). Comparable as the competitive context for OTR's metabolic and oncology ambitions and as a partner signal via LAV (Lilly Asia Ventures).
• Pfizer: Global pharma with strategic venture arm (Pfizer Ventures) that participated in OTR's Series A. Comparable as both a likely future BD counterparty and as the dominant competitive benchmark across oncology, I&I, and cardiometabolic.

Emerging players

• Recursion Pharmaceuticals: AI-native biotech using high-throughput biology and machine learning to advance a broad pipeline of small molecules. Comparable on the AI/ML-augmented discovery narrative and platform-based R&D model, though with much larger headcount and public listing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OTR Therapeutics